公司資料
Spero Therapeutics 股價、新聞與催化劑
- 股票代碼:
- SPRO
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
1.22 USD (+0.83%)
收盤價
最後更新: 2026年8月21日
164M USD
市值
股價為何變動
As of Aug 21, 2026, SPRO closed up 0.83% at $1.22. No new same-company headline was identified in the current news window.
公司概覽
Immunology and Inflammation Company
Spero Therapeutics is a clinical-stage biopharmaceutical company developing medicines for serious immune-mediated diseases. Its internal strategy now centers on CD40 ligand inhibition.
SP001
SP001 is a third-generation, Fc-silent monoclonal antibody targeting CD40 ligand. The molecule is designed to suppress pathogenic immune-cell interactions while reducing the platelet-activation concerns associated with earlier anti-CD40L antibodies.
IgG4-Related Disease
Spero plans to develop SP001 first in IgG4-related disease, a rare chronic fibroinflammatory disorder that can damage multiple organs. The company also sees potential applications across additional immunologic and inflammatory diseases.
Utebzi Economics
Utebzi is an FDA-approved oral carbapenem antibiotic for certain adults with complicated urinary tract infections, including pyelonephritis. GSK controls U.S. and European commercialization, while Spero retains exposure to milestones and royalties.
未來催化劑
- U.S. commercial availability of Utebzi through GSK by the end of 2026.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。